-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Gossamer Bio to Underweight, Lowers Price Target to $0.3

Benzinga·02/24/2026 13:28:54
Listen to the news
Barclays analyst Eliana Merle downgrades Gossamer Bio (NASDAQ:GOSS) from Overweight to Underweight and lowers the price target from $9 to $0.3.